Long Non-coding RNA EPIC1 Promotes Cell Proliferation and Motility and Drug Resistance in Glioma

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2020 Apr 24

PMID 32322669

Citations 15

Authors

Jianjiao Wang

Shuguang Yang

Qiongyu Ji

Qingsong Li

Fenggang Zhou

Yang Li

Fei Yuan

Jie Liu

Yu Tian

Yan Zhao

Yongri Zheng

Affiliations

Soon will be listed here.

Abstract

Evidence has revealed that long non-coding RNAs (lncRNAs) are involved in carcinogenesis and tumor progression. lncRNAs play an important role in regulation of numerous cellular processes including cell proliferation, apoptosis, cell cycle, differentiation, and motility. Several studies have demonstrated that lncRNA EPIC1 governs cell growth, cell cycle, migration, invasion, and drug resistance in human malignancies. However, the role of EPIC1 and its underlying molecular mechanisms in glioma have not been investigated. In this study, we determined the function of EPIC1 in glioma cells via upregulation or downregulation of EPIC1. We further dissected the mechanism of EPIC1-mediated tumor progression in glioma. Our results showed that inhibition of EPIC1 suppressed cell viability, induced apoptosis, inhibited cell invasion, and increased cell sensitivity to temozolomide in glioma cells. Consistently, overexpression of EPIC1 exhibited the opposite effects in glioma cells. Moreover, our data suggest that EPIC1 exerts its biological functions via targeting Cdc20 in glioma cells. In line with this, overexpression of Cdc20 reversed the EPIC1-mediated tumor progression in glioma cells. Therefore, targeting EPIC1 might be a useful approach for glioma treatment.

Citing Articles

New sights on long non-coding RNAs in glioblastoma: A review of molecular mechanism.

Bagheri-Mohammadi S, Karamivandishi A, Mahdavi S, Siahposht-Khachaki A Heliyon. 2024; 10(21):e39744.

PMID: 39553554 PMC: 11564028. DOI: 10.1016/j.heliyon.2024.e39744.

Non-coding RNAs as therapeutic targets in cancer and its clinical application.

Leng X, Zhang M, Xu Y, Wang J, Ding N, Yu Y J Pharm Anal. 2024; 14(7):100947.

PMID: 39149142 PMC: 11325817. DOI: 10.1016/j.jpha.2024.02.001.

Bioinformatics analysis and experimental validation reveal that CDC20 overexpression promotes bladder cancer progression and potential underlying mechanisms.

Liu Y, Zou S, Gao X Genes Genomics. 2024; 46(4):437-449.

PMID: 38438666 DOI: 10.1007/s13258-024-01505-x.

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance.

Sadida H, Abdulla A, Al Marzooqi S, Hashem S, Macha M, Akil A Transl Oncol. 2023; 39:101821.

PMID: 37931371 PMC: 10654239. DOI: 10.1016/j.tranon.2023.101821.

Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer.

Cheng C, Liu D, Liu Z, Li M, Wang Y, Sun B Cancer Sci. 2022; 113(9):2986-3001.

PMID: 35534983 PMC: 9459417. DOI: 10.1111/cas.15388.

References

Wahlestedt C . Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013; 12(6):433-46. DOI: 10.1038/nrd4018. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Wang L, He Z . Functional Roles of Long Non-Coding RNAs (LncRNAs) in Glioma Stem Cells. Med Sci Monit. 2019; 25:7567-7573. PMC: 6795106. DOI: 10.12659/MSM.916040. View

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M . Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol Med Chir (Tokyo). 2018; 58(10):405-421. PMC: 6186761. DOI: 10.2176/nmc.ra.2018-0141. View

Bahadur S, Sahu A, Baghel P, Saha S . Current promising treatment strategy for glioblastoma multiform: A review. Oncol Rev. 2019; 13(2):417. PMC: 6661528. DOI: 10.4081/oncol.2019.417. View

Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J . Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities. Front Oncol. 2019; 9:41. PMC: 6369148. DOI: 10.3389/fonc.2019.00041. View

Alinezhad A, Jafari F . Novel management of glioma by molecular therapies, a review article. Eur J Transl Myol. 2019; 29(3):8209. PMC: 6767997. DOI: 10.4081/ejtm.2019.8209. View

Xie Q, Wu Q, Mack S, Yang K, Kim L, Hubert C . CDC20 maintains tumor initiating cells. Oncotarget. 2015; 6(15):13241-54. PMC: 4537011. DOI: 10.18632/oncotarget.3676. View

Di Carlo D, Cagnazzo F, Benedetto N, Morganti R, Perrini P . Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis. Neurosurg Rev. 2017; 42(2):263-275. DOI: 10.1007/s10143-017-0928-7. View

10.

Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y . lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell. 2018; 33(4):706-720.e9. PMC: 6143179. DOI: 10.1016/j.ccell.2018.03.006. View

11.

Li C, Hu G, Wei B, Wang L, Liu N . lncRNA LINC01494 Promotes Proliferation, Migration And Invasion In Glioma Through miR-122-5p/CCNG1 Axis. Onco Targets Ther. 2019; 12:7655-7662. PMC: 6756415. DOI: 10.2147/OTT.S213345. View

12.

Wang J, Zhou F, Li Y, Li Q, Wu Z, Yu L . Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition. Cell Cycle. 2017; 16(24):2355-2365. PMC: 5788407. DOI: 10.1080/15384101.2017.1388972. View

13.

Xin S, Huang K, Zhu X . Non-coding RNAs: Regulators of glioma cell epithelial-mesenchymal transformation. Pathol Res Pract. 2019; 215(9):152539. DOI: 10.1016/j.prp.2019.152539. View

14.

Taylor M, Das B, Ray S . Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis. 2018; 23(11-12):563-575. PMC: 6193815. DOI: 10.1007/s10495-018-1480-9. View

15.

Li Y, Cai Q, Li W, Feng F, Yang L . Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth. Biochem Biophys Res Commun. 2018; 504(4):654-659. DOI: 10.1016/j.bbrc.2018.08.174. View

16.

Wang J, Yang Y, Cao Y, Tang X . miR‑342 inhibits glioma cell proliferation by targeting GPRC5A. Mol Med Rep. 2019; 20(1):252-260. PMC: 6579993. DOI: 10.3892/mmr.2019.10242. View

17.

Mao D, Gujar A, Mahlokozera T, Chen I, Pan Y, Luo J . A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Rep. 2015; 11(11):1809-21. PMC: 4481182. DOI: 10.1016/j.celrep.2015.05.027. View

18.

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

19.

Grek C, Sheng Z, Naus C, Sin W, Gourdie R, Ghatnekar G . Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol. 2018; 41:79-88. PMC: 6292445. DOI: 10.1016/j.coph.2018.05.002. View

20.

Wang Y, Wang Z, Xu J, Li J, Li S, Zhang M . Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun. 2018; 9(1):3192. PMC: 6085336. DOI: 10.1038/s41467-018-05495-9. View